Trial reportJournal of human hypertension2007
A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension.
Trial report in Journal of human hypertension, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension.The Cochrane database of systematic reviews · 2020Pooled it
- Blood pressure lowering efficacy of renin inhibitors for primary hypertension.The Cochrane database of systematic reviews · 2017Pooled it
- Aliskiren reduces home blood pressure and albuminuria in patients with hypertensive nephrosclerosis.Clinical and experimental nephrology · 2013Trial
- Renin Inhibition with Aliskiren: A Decade of Clinical Experience.Journal of clinical medicine · 2017Review
- Proteinuria and its relation to cardiovascular disease.International journal of nephrology and renovascular disease · 2013Review
- Oral renin inhibitors in clinical practice: a perspective review.Therapeutic advances in chronic disease · 2012Article
- Renin inhibitors.Journal of clinical hypertension (Greenwich, Conn.) · 2011Review
- Renin and cardiovascular disease: Worn-out path, or new direction.World journal of cardiology · 2011Article
- Efficacy of aliskiren/hydrochlorothiazide combination for the treatment of hypertension: a meta-analytical approach.The open cardiovascular medicine journal · 2011Article
- New class of agents for treatment of hypertension: focus on direct renin inhibition.Vascular health and risk management · 2010Review
- Renoprotection, renin inhibition, and blood pressure control: the impact of aliskiren on integrated blood pressure control.Integrated blood pressure control · 2010Article
- First-line treatment of hypertension: critical appraisal of potential role of aliskiren and hydrochlorothiazide in a fixed combination.Integrated blood pressure control · 2010Article
- Factors correlated with plasma renin activity in general Japanese population.Clinical and experimental nephrology · 2009Article
- Direct renin inhibition: clinical pharmacology.Journal of molecular medicine (Berlin, Germany) · 2008Review
- Renin inhibitors, clinical experience.Journal of molecular medicine (Berlin, Germany) · 2008Review
- Aliskiren (tekturna), a novel antihypertensive approach to inhibition of the Renin-Angiotensin-aldosterone system.P & T : a peer-reviewed journal for formulary management · 2008Article
- Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy.Vascular health and risk management · 2008Review
- The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction.Vascular health and risk management · 2008Review
- Renin inhibitors: optimal strategy for renal protection.Current hypertension reports · 2007Review
- The 2007 revised ESC/ESH Guidelines in the management of hypertension: clarifying individual patient care.Journal of human hypertension · 2007Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with severe hypertension (>180/110 mm Hg) require large blood pressure (BP) reductions to reach recommended treatment goals (<140/90 mm Hg) and usually require combination therapy to do so. This 8-week, multicenter, randomized, double-blind, parallel-group study compared the tolerability and antihypertensive efficacy of the novel direct renin inhibitor aliskiren with the angiotensin converting enzyme inhibitor lisinopril in patients with severe hypertension (mean sitting diastolic blood pressure (msDBP)>or=105 mm Hg and <120 mm Hg). In all, 183 patients were randomized (2:1) to aliskiren 150 mg (n=125) or lisinopril 20 mg (n=58) with dose titration (to aliskiren 300 mg or lisinopril 40 mg) and subsequent addition of hydrochlorothiazide (HCTZ) if additional BP control was required. Aliskiren-based treatment (ALI) was similar to lisinopril-based treatment (LIS) with respect to the proportion of patients reporting an adverse event (AE; ALI 32.8%; LIS 29.3%) or discontinuing treatment due to AEs (ALI 3.2%; LIS 3.4%). The most frequently reported AEs in both groups were headache, nasopharyngitis and dizziness. At end point, ALI showed similar mean reductions from baseline to LIS in msDBP (ALI -18.5 mm Hg vs LIS -20.1 mm Hg; mean treatment difference 1.7 mm Hg (95% confidence interval (CI) -1.0, 4.4)) and mean sitting systolic blood pressure (ALI -20.0 mm Hg vs LIS -22.3 mm Hg; mean treatment difference 2.8 mm Hg (95% CI -1.7, 7.4)). Responder rates (msDBP<90 mm Hg and/or reduction from baseline>or=10 mm Hg) were 81.5% with ALI and 87.9% with LIS. Approximately half of patients required the addition of HCTZ to achieve BP control (ALI 53.6%; LIS 44.8%). In conclusion, ALI alone, or in combination with HCTZ, exhibits similar tolerability and antihypertensive efficacy to LIS alone, or in combination with HCTZ, in patients with severe hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.